NCT04876456 - A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Germ Cell TumorSeminomaNon-seminomatous Germ Cell TumorOvarian Germ Cell Tumor

Interventions

DRUG

Cabozantinib

Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.

Trial Locations (1)

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis